[go: up one dir, main page]

WO2010011922A3 - Nouveaux sels cristallins d’epalrestat - Google Patents

Nouveaux sels cristallins d’epalrestat Download PDF

Info

Publication number
WO2010011922A3
WO2010011922A3 PCT/US2009/051687 US2009051687W WO2010011922A3 WO 2010011922 A3 WO2010011922 A3 WO 2010011922A3 US 2009051687 W US2009051687 W US 2009051687W WO 2010011922 A3 WO2010011922 A3 WO 2010011922A3
Authority
WO
WIPO (PCT)
Prior art keywords
crystalline salts
novel crystalline
epalrestat
relates
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/051687
Other languages
English (en)
Other versions
WO2010011922A2 (fr
Inventor
Isabel Kalofonos
G. Patrick Stahly
William Martin-Doyle
Dimitris Kalofonos
Jeffrey S. Stults
Travis L. Houston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionevia Pharmaceuticals Inc
Original Assignee
Bionevia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionevia Pharmaceuticals Inc filed Critical Bionevia Pharmaceuticals Inc
Priority to EA201100244A priority Critical patent/EA018600B1/ru
Publication of WO2010011922A2 publication Critical patent/WO2010011922A2/fr
Publication of WO2010011922A3 publication Critical patent/WO2010011922A3/fr
Priority to US13/013,786 priority patent/US8697735B2/en
Anticipated expiration legal-status Critical
Priority to US14/251,039 priority patent/US9447056B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Cette invention concerne de nouveaux sels cristallins de l’acide 5-[(lZ,2E)-2-méthyl-3-phénylpropénylidène]-4-oxo-2-thioxo-3-thiazolidine acétique. L’invention concerne aussi la préparation et la caractérisation des sels cristallins selon les différents modes de réalisation de l’invention. L’invention concerne par ailleurs des compositions pharmaceutiques contenant les nouveaux sels cristallins et leur utilisation thérapeutique pour traiter et/ou prévenir différentes pathologies, notamment les complications diabétiques, l’inhibition de l’aldose réductase et la cardioprotection chez les patients éventuellement non diabétiques.
PCT/US2009/051687 2008-07-25 2009-07-24 Nouveaux sels cristallins d’epalrestat Ceased WO2010011922A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EA201100244A EA018600B1 (ru) 2008-07-25 2009-07-24 Новые кристаллические соли эпалрестата
US13/013,786 US8697735B2 (en) 2008-07-25 2011-01-25 Solid forms of epalrestat
US14/251,039 US9447056B2 (en) 2008-07-25 2014-04-11 Solid forms of epalrestat

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8361108P 2008-07-25 2008-07-25
US61/083,611 2008-07-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/051693 Continuation-In-Part WO2010011926A2 (fr) 2008-07-25 2009-07-24 Nouveau co-cristal de bétaïne d'épalrestat

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/013,786 Continuation-In-Part US8697735B2 (en) 2008-07-25 2011-01-25 Solid forms of epalrestat
US13/013,786 Continuation US8697735B2 (en) 2008-07-25 2011-01-25 Solid forms of epalrestat

Publications (2)

Publication Number Publication Date
WO2010011922A2 WO2010011922A2 (fr) 2010-01-28
WO2010011922A3 true WO2010011922A3 (fr) 2010-04-22

Family

ID=41570881

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/051687 Ceased WO2010011922A2 (fr) 2008-07-25 2009-07-24 Nouveaux sels cristallins d’epalrestat

Country Status (2)

Country Link
EA (1) EA018600B1 (fr)
WO (1) WO2010011922A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697735B2 (en) 2008-07-25 2014-04-15 Bionevia Pharmaceuticals, Inc. Solid forms of epalrestat
WO2010028132A2 (fr) 2008-09-06 2010-03-11 Bionevia Pharmaceuticals, Inc. Nouveaux co-cristaux de choline et d'épalrestat
RU2013135224A (ru) 2011-01-20 2015-03-10 Бионевиа Фармасьютикалс Инк. Композиции с модифицированным высвобождением эпалрестата или его производных и способы их использования
JP6976047B2 (ja) * 2015-08-28 2021-12-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 エパルレスタットを調製する方法
CN113336718B (zh) * 2021-06-01 2023-02-28 天津大学 依帕司他-二甲双胍盐及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831045A (en) * 1980-08-22 1989-05-16 Ono Pharmaceutical Co., Ltd. Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient
EP1106210A2 (fr) * 1999-12-07 2001-06-13 Pfizer Products Inc. Combinaisons pour le traitement de complications diabétiques, comprenant un inhibiteur de reductase d'aldose et un agents antihypertensif
JP2007099680A (ja) * 2005-10-04 2007-04-19 Konica Minolta Chemical Co Ltd エパルレスタット製造法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831045A (en) * 1980-08-22 1989-05-16 Ono Pharmaceutical Co., Ltd. Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient
EP1106210A2 (fr) * 1999-12-07 2001-06-13 Pfizer Products Inc. Combinaisons pour le traitement de complications diabétiques, comprenant un inhibiteur de reductase d'aldose et un agents antihypertensif
JP2007099680A (ja) * 2005-10-04 2007-04-19 Konica Minolta Chemical Co Ltd エパルレスタット製造法

Also Published As

Publication number Publication date
WO2010011922A2 (fr) 2010-01-28
EA018600B1 (ru) 2013-09-30
EA201100244A1 (ru) 2011-08-30

Similar Documents

Publication Publication Date Title
WO2010028132A3 (fr) Nouveaux co-cristaux de choline et d'épalrestat
WO2010114824A8 (fr) Dérivés d'azoanthracène substitués, compositions pharmaceutiques et leurs procédés d'utilisation
WO2010001169A3 (fr) Composés chimiques 251
WO2010011926A3 (fr) Nouveau co-cristal de bétaïne d'épalrestat
WO2008108957A3 (fr) Dérivés pipéridines et leurs procédés d'utilisation
WO2011049327A3 (fr) Composition de soin externe pour la peau comprenant un sel et du sucre en tant que principes actifs pour prévenir et traiter la vaginose et utilisation de cette composition
WO2008116129A3 (fr) Analogues d'imidazolopyrimidine et leur utilisation comme inhibiteurs de pi3 kinase et de mtor
WO2007127273A3 (fr) Procédés et compositions permettant de modifier la fonction cellulaire
WO2008054454A3 (fr) Dérivés hétérocycliques contenant de l'azote, compositions pharmaceutiques, et leurs procédés d'utilisations en tant qu'agents antiviraux
WO2007137066A3 (fr) Inhibiteurs hétérocycliques de la déshydrogénase du stéroïde hydroxyle 11-b de type 1 et leurs procédés d'utilisation
WO2008120713A1 (fr) Composition médicinale, aliment ou boisson ayant un effet d'augmentation des actions nerveuses parasympathiques
WO2008070859A3 (fr) Traitement d'affections cutanées par dickkopf1 (dkk1)
WO2008108958A3 (fr) Dérivés de benzimidazole et leurs procédés d'utilisation
WO2009139576A3 (fr) Dérivés de pyridine substitués avec de nouveaux benzoxazoles ou des sels pharmaceutiquement acceptables de ces composés, procédé de préparation de ces composés et compositions pharmaceutiques contenant ces composés comme principes actifs destinées à la prévention et au traitement d'une maladie à croissance cellulaire anormale
WO2010135530A3 (fr) Composés, compositions et procédés pour moduler des taux d'acide urique
WO2010074588A3 (fr) Composés pharmaceutiques
WO2009145456A3 (fr) Dérivés hétérocycliques
WO2009109618A3 (fr) Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l’expression de mcp-1, cx3cr1 et p40
WO2009091550A8 (fr) Dérivés de 2,3-dihydroimidazo [1,2-c] quinazoline à substitution sulfone utilisés pour traiter des troubles hyperproliférants et des maladies associées à l'angiogénèse
WO2010090494A3 (fr) Utilisation médicale de dérivés d'acide 5-benzylaminosalicylique ou de sels correspondants
WO2009109616A3 (fr) Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l'expression de mcp-1, cx3cr1 et p40
WO2008011173A3 (fr) Amélioration des concentrations ou de l'activité de l'arginase
WO2009134616A3 (fr) Nouveaux inhibiteurs de réplication du virus de l’hépatite c
WO2009022899A8 (fr) Gel à base de pirfénidone
WO2010011922A3 (fr) Nouveaux sels cristallins d’epalrestat

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09801067

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201100244

Country of ref document: EA

122 Ep: pct application non-entry in european phase

Ref document number: 09801067

Country of ref document: EP

Kind code of ref document: A2